Senolytic Fisetin
Fisetin (3,3',4',7-tetrahydroxyflavone) is a naturally occurring flavonoid found in strawberries, apples, persimmons, onions, grapes, and cucumbers. It has emerged as one of the most potent senolytic compounds identified in preclinical research, meaning it can selectively eliminate senescent (aged, dysfunctional) cells that accumulate with aging and contribute to chronic inflammation, tissue dysfunction, and age-related diseases.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
Selectively induces apoptosis in senescent cells by inhibiting pro-survival pathways including PI3K/AKT/mTOR and BCL-2 family anti-apoptotic proteins (BCL-XL) that senescent cells depend on for survival, while sparing normal healthy cells.
Activates SIRT1 (sirtuin 1) and AMPK pathways involved in cellular stress response, autophagy, and metabolic regulation, contributing to anti-aging effects independent of senolytic activity.
Inhibits NF-kB signaling and reduces production of SASP (senescence-associated secretory phenotype) factors including IL-6, IL-8, TNF-alpha, and MMP-3, which are key drivers of age-related chronic inflammation and tissue damage.
Days 1-7: Senescent cells begin undergoing apoptosis during and shortly after the dosing window. No dramatic subjective effects expected.
Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.
Acute or intermittent fisetin reduced senescence markers in progeroid and old mice.
Acute or intermittent treatment of progeroid and old mice with fisetin reduced senescence markers in multiple tissues, consistent with a hit-and-run senolytic mechanism.
Fisetin is a senotherapeutic that extends health and lifespan.
Evidence scope. Animal; preclinical senolytic evidence.
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 500-2,000 mg orally for 2-3 days monthly. The human design found used 20 mg/kg on days 1-3 every 14 days, not this regimen.
Detailed pathway claims. The selected abstract did not establish every listed pathway in humans.
Primary safety. No completed human trial abstract established it.
Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.
Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.
(parent compound). Rapidly metabolized to glucuronide and sulfate conjugates. Very low oral bioavailability (~1-5% in animal studies).
Oral
Oral (rapid glucuronidation and sulfation)
Senolytic apoptosis cascade continues after compound clearance
Hepatic (rapid phase II metabolism via glucuronidation and sulfation)
Storage. Store in a cool, dry place away from light and moisture. Oral compound - no reconstitution needed. Some formulations recommend refrigeration for long-term storage.
Dietary supplement (OTC) in the United States. Not FDA-approved for any medical indication. GRAS as a food component. Multiple clinical trials registered at ClinicalTrials.gov (including AFFIRM at Mayo Clinic). Not a controlled substance.
Put it to work
Open Fisetin straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open Fisetin in the app →Go deeper
The complete Fisetin walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗Track it in OnePin. Log vials, draws, and protocols in the app.
Type a name, brand, or tool. Esc closes.